Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.765
EU - Europa 4.341
AS - Asia 3.740
SA - Sud America 649
Continente sconosciuto - Info sul continente non disponibili 474
AF - Africa 101
OC - Oceania 9
Totale 21.079
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.573
SG - Singapore 1.439
RU - Federazione Russa 1.107
CN - Cina 979
IT - Italia 783
FI - Finlandia 658
BR - Brasile 465
DE - Germania 444
HK - Hong Kong 334
VN - Vietnam 298
GB - Regno Unito 215
UA - Ucraina 213
PL - Polonia 202
IE - Irlanda 183
FR - Francia 167
JP - Giappone 129
SE - Svezia 124
CA - Canada 112
KR - Corea 111
IN - India 106
BD - Bangladesh 68
RO - Romania 56
AR - Argentina 52
TR - Turchia 48
BE - Belgio 47
IQ - Iraq 42
EC - Ecuador 34
CO - Colombia 32
NL - Olanda 30
VE - Venezuela 30
MX - Messico 28
CI - Costa d'Avorio 27
ES - Italia 26
UZ - Uzbekistan 21
AT - Austria 20
MY - Malesia 18
ZA - Sudafrica 18
MA - Marocco 17
PH - Filippine 17
IR - Iran 16
CH - Svizzera 14
CR - Costa Rica 14
ID - Indonesia 13
LB - Libano 11
PK - Pakistan 11
SA - Arabia Saudita 11
CL - Cile 10
UY - Uruguay 10
DZ - Algeria 8
KE - Kenya 8
NP - Nepal 8
AU - Australia 7
JM - Giamaica 7
KZ - Kazakistan 7
PY - Paraguay 7
CZ - Repubblica Ceca 6
EE - Estonia 6
EG - Egitto 6
IL - Israele 6
PA - Panama 6
PE - Perù 6
TW - Taiwan 6
EU - Europa 5
JO - Giordania 5
LU - Lussemburgo 5
PS - Palestinian Territory 5
TN - Tunisia 5
AL - Albania 4
AZ - Azerbaigian 4
BY - Bielorussia 4
HU - Ungheria 4
KG - Kirghizistan 4
LT - Lituania 4
NI - Nicaragua 4
SV - El Salvador 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
GE - Georgia 3
GR - Grecia 3
QA - Qatar 3
RS - Serbia 3
BG - Bulgaria 2
BH - Bahrain 2
GT - Guatemala 2
HN - Honduras 2
LV - Lettonia 2
NO - Norvegia 2
SI - Slovenia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
Totale 20.593
Salva come PNG Salva come JPEG
Città #
Fairfield 1.439
Ashburn 1.384
Singapore 938
Woodbridge 765
San Jose 717
Seattle 577
Wilmington 576
Chandler 572
Houston 550
Cambridge 527
Ann Arbor 494
Hong Kong 324
Council Bluffs 235
Moscow 201
Palermo 186
Dublin 175
Zgierz 170
Beijing 167
Santa Clara 151
Medford 143
Los Angeles 141
Des Moines 130
Altamura 118
New York 116
Tokyo 116
Nanjing 112
Boardman 111
Helsinki 109
Jacksonville 109
Ho Chi Minh City 98
Chicago 93
Dallas 92
Princeton 90
The Dalles 86
Lawrence 80
Lauterbourg 79
San Diego 78
Frankfurt am Main 72
Hanoi 68
Phoenix 67
Hefei 52
Dearborn 50
São Paulo 47
Brussels 46
London 45
Tulsa 42
Buffalo 41
Orem 40
Ludwigshafen am Rhein 39
Changsha 37
Seoul 35
Nanchang 33
Shenyang 33
Denver 32
Jiaxing 31
Tianjin 31
Hebei 29
Abidjan 27
Bremen 27
Panama City 27
Toronto 27
Izmir 26
Munich 25
Warsaw 25
Chennai 24
Da Nang 23
Jinan 23
Montreal 23
Nuremberg 23
Kitzingen 22
Guangzhou 21
Kumar 21
Milan 21
Rome 21
Brooklyn 20
Saint Petersburg 20
Seongnam 20
Baghdad 19
Zhengzhou 18
Atlanta 17
Washington 17
Belo Horizonte 16
Columbus 16
Ningbo 16
San Paolo di Civitate 15
Brasília 14
Hangzhou 14
Amsterdam 13
Rio de Janeiro 13
Springfield 13
Stockholm 13
Turku 13
Venice 13
Boydton 12
Haiphong 12
Philadelphia 12
Poplar 12
San José 12
Tashkent 12
Las Vegas 11
Totale 13.708
Salva come PNG Salva come JPEG
Nome #
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 371
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 355
Dietary restriction: could it be considered as speed bump on tumor progression road? 338
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 324
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 320
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? 317
Anti-endothelin drugs in solid tumors 312
EGF Induces STAT3-Dependent VEGF Expression in HT-29 colon cancer cells 311
I tumori della mammella e/o dell’ovaio di tipo eredofamiliare: strategie di prevenzione nelle donne ad alto rischio 311
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 309
A headlight on liquid biopsies: a challenging tool for breast cancer management 309
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 298
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 298
How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes? 291
BRCA1 and BRCA2 germline mutations in sicilian breast and/or ovarian cancer families and their association with familial profiles 290
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 287
BRCA1 and BRCA2 variants of uncertain clinical significance and their implications for genetic counseling 282
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 281
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 281
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies 279
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 276
Monoclonal antibodies in gastrointestinal cancers 274
Targeted Therapies in Hepatocellular Carcinoma 272
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 269
Nintedanib in NSCLC: Evidence to date and place in therapy 264
Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors 260
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 260
Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines 259
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 259
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 258
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 258
Cancer and the microbiome: Potential applications as new tumor biomarker 258
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 256
EGFR genomic alterations in cancer: prognostic and predictive values 255
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 253
The role of targeted therapy for gastrointestinal tumors 251
Downregulated expression of Cdc25A gene in MCF-7 breast cancer cell 249
MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? 249
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 248
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 245
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 244
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients 243
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 243
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 242
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 233
Multisciplinary management of patients with liver metastasis from colorectal cancer 233
Sex steroids, carcinogenesis, and cancer progression 233
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 232
Well-being among Italian medical oncologists: An exploratory study 231
HER2-positive male breast cancer: An update 231
A literature-based meta-analysis of the comparison between Gemcitabine-based combination and monochemotherapy for the treatment of advanced non-small cell lung cancer in elderly patients 228
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor 227
Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy? 222
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 216
Bortezomib: a new pro-apoptotic agent in cancer treatment. 214
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 214
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules 212
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 211
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? 210
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 210
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 209
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 208
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 198
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 197
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 196
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 193
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 193
A non common BRAF mutation c1799-1801 delTGA identified in sporadic colon rectal cancer of sicilian patients 191
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 188
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 186
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 185
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 183
Comparison between gemcitabine-based combination (G) and single-agent chemotherapy (S) for elderly patients (EP) with advanced non-small cell lung cancer (NSCLC): A literature-based meta-analysis. 182
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 179
Low dose splenic irradiation in myelofibrosis: outcomes and toxicity of three radiation schedule 177
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 176
Impact of the new 5-HT3 receptor antagonist palonosetron (P) in chemotherapy-induced nausea and vomiting (CINV) control in elderly advanced breast cancer (EABC) patients: Comparison with the classic antiemetic agent ondansetron (O). 176
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 167
An all-oral combination regimen of vinorelbine and capecitabine for elderly patients with metastatic breast cancer 166
Serum levels of angiogenetic cancer biomarkers in men undergoing prostate biopsy. Preliminary data 165
Capecitabine (XEL) + Oxaliplatin (OX) in elderly people (EP) with Colorectal Cancer (CRC): Comparison of safety (S) and feasibility (F) of two different schedules. Preliminary findings 164
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 164
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 161
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 161
Apoptosis in Thyroid Autoimunity. 159
VIPoma and PPoma 155
Efficacy of weekly low-dose chemotherapy in elderly women with advanced ovarian cancer: is there an antiangiogenic effect? 154
Ramucirumab and its use in gastric cancer treatment 147
Safety and efficacy of two different schedules of capecitabine combined with oxaliplatin in the treatment of colon cancer in the elderly 120
RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE 113
Totale 21.079
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.559
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.559
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022903 0 0 0 64 63 50 72 86 117 153 102 196
2022/20231.649 176 354 31 197 183 230 109 110 154 6 67 32
2023/2024666 29 87 51 51 47 132 64 86 7 10 9 93
2024/20251.855 25 151 184 136 60 66 111 190 99 190 250 393
2025/20266.225 523 200 329 474 626 916 810 733 449 694 223 248
2026/20271.608 367 244 942 55 0 0 0 0 0 0 0 0
Totale 21.079